DEF: Pro-Dex Reports 10th Year of Sales Growth, Eyes FY26 Expansion

Pro-Dex, Inc. announced its tenth consecutive year of sales growth, reaching $65 million in Fiscal 2025, and outlined proposals for its upcoming annual shareholder meeting.

Summary

• Fiscal 2025 sales reached $65 million, marking a 24% year-over-year growth and the tenth consecutive year of sales growth.
• The company assisted customers with major product launches, added depth to its management team, and improved manufacturing systems.
• Pro-Dex is well-positioned for another strong year in Fiscal 2026 due to a healthy backlog, new customers, and new products/technology in development.
• The Annual Meeting of Shareholders will be held on November 20, 2025, to elect seven directors, ratify Baker Tilly US, LLP as independent auditors, hold advisory votes on executive compensation, and amend the 2016 Equity Incentive Compensation Plan.
• The 2016 Equity Incentive Plan amendment seeks to extend its term for an additional ten years, through September 30, 2036, to continue attracting and retaining employees.
• Outstanding shares of Common Stock as of September 23, 2025, were 3,280,004.
• Nicholas J. Swenson beneficially owns 31.2% of Common Stock, and all directors, director nominees, and Named Executive Officers as a group own 45.9%.
• The Board recommends voting FOR all seven director nominees, FOR proposals 2, 3, and 5, and FOR a 1-year frequency for future advisory votes on executive compensation (Proposal 4).

Sentiment

Score: 8

Explanation: The filing presents a very positive outlook with strong financial performance, including significant sales growth and a healthy backlog. The proposed extension of the equity incentive plan and the focus on new products and customers indicate confidence in future growth. The increase in net income from FY24 to FY25 is substantial.

Positives

• Achieved tenth consecutive year of sales growth.
• Fiscal 2025 sales grew 24% year-over-year to $65 million.
• Successfully assisted customers with major product launches.
• Strengthened the management team by adding depth.
• Improved manufacturing systems.
• Maintains a healthy backlog, new customers, and new products/technology in development, positioning for a strong Fiscal 2026.
• The 2016 Equity Incentive Plan amendment aims to attract and retain highly qualified employees by offering various equity incentives.

Risks

• The Board actively oversees management of credit, liquidity, operations, financial, and cyber risks.
• Compensation plans are designed to avoid encouraging excessive risk-taking, with mitigating factors such as capped incentives, bonus payments based on audited results, multiple performance objectives, and multi-level review processes.

Future Outlook

Pro-Dex is well-positioned for another strong year in Fiscal 2026, supported by a healthy backlog, new customer acquisitions, and ongoing development of new products and technology. The company remains committed to its plans for continued growth.

Management Comments

• "Thank you for your continued support of Pro-Dex."
• "In Fiscal 2025, we continued our trend with our tenth consecutive years of sales growth, including 24% year-over-year growth finishing at $65M in sales."
• "Other highlights include assisting customers with major product launches, adding depth to our management team, and improving our manufacturing systems."
• "As always, Pro-Dex remains committed to its plans for continued growth."
• "Between a healthy backlog, new customers, and new products and technology in development, we believe Pro-Dex is well positioned for another strong year in Fiscal 2026."
• "We cannot discuss the past, and upcoming, accomplishments without a word of thanks and appreciation for our Pro-Dex teammates, including our Board of Directors. Their efforts and dedication make this all possible."

Industry Context

The company operates in the medical device industry, a primary target market for its engineering and management expertise. Its directors have extensive experience in this sector, including spine-focused medical devices, which is identified as a potential area for future revenue growth. The continued sales growth and focus on new products suggest a competitive stance within this specialized market.

Comparison to Industry Standards

• The filing does not provide specific industry benchmarks or comparable company results to assess against global standards.
• The company's investment in Monogram Technologies Inc. (formerly Monogram Orthopaedics Inc.), a company developing patient-optimized orthopedic implants using 3D printing and robotics, indicates engagement with advanced technologies within the orthopedic sector.
• The directors' experience with companies like Medtronic, Inc. (NYSE: MDT), Nuvasive, and Arthrocare, Inc. (Nasdaq: ARTC) suggests a leadership team with exposure to industry leaders, though no direct performance comparison is made.

Management Changes

Corporate Governance

Related Party Transactions

• Investment of $1.0 million in marketable equity securities of Air T, Inc. (Nasdaq: AIRT). Two Board members, Nicholas J. Swenson (Chairman and CEO of Air T) and Raymond E. Cabillot (Board member of Air T), are also board members of Air T, Inc. and own equity interests. Katrina M.K. Philp, another Board member, is Chief of Staff at Air T, Inc. These purchases were made through 10b5-1 Plans and approved by independent Board members.
• Ownership of 2,126,673 shares of Monogram Technologies Inc. (Nasdaq: MGRM) common stock, with an estimated fair value of $5.7 million as of June 30, 2025. Rick Van Kirk, the company's CEO, has been a member of Monogram's board of directors since 2017.
• Indemnification agreements with each director and executive officer, requiring indemnification to the fullest extent permitted by Colorado law.

Stakeholder Impact

• Shareholders: Direct impact through proposed director elections, ratification of auditors, advisory votes on executive compensation, and the amendment to the equity incentive plan. The strong sales growth and positive outlook are beneficial.
• Employees: The proposed extension of the 2016 Equity Incentive Plan aims to attract and retain valuable employees through equity incentives, linking their success to the company's long-term goals.
• Management: Executive compensation is tied to company and individual performance, with a philosophy of competitive pay and sustained performance.

Next Steps

• Annual Meeting of Shareholders to be held on November 20, 2025.
• Shareholders to vote on the election of seven directors.
• Shareholders to ratify the appointment of Baker Tilly US, LLP as independent registered public accounting firm for fiscal year ending June 30, 2026.
• Shareholders to hold an advisory vote to approve the compensation of Named Executive Officers.
• Shareholders to hold an advisory vote on the frequency of future advisory votes to approve executive compensation.
• Shareholders to vote on amending the 2016 Equity Incentive Compensation Plan to extend its term for an additional ten years.
• Shareholder proposals for the 2026 annual meeting must be received by June 12, 2026.

Key Dates

Recommendation

The company has demonstrated exceptional financial performance with its tenth consecutive year of sales growth, including a robust 24% year-over-year increase to $65 million in Fiscal 2025. The substantial increase in net income from $2.127 million in FY2024 to $8.978 million in FY2025 indicates strong profitability and operational efficiency. Management's forward-looking statements, citing a healthy backlog, new customers, and new product development, suggest continued positive momentum for Fiscal 2026. The proposed extension of the equity incentive plan is a strategic move to attract and retain talent, further aligning employee interests with shareholder value. The strong financial results and optimistic outlook make this a compelling investment opportunity.

Keywords

Pro-Dex, SEC Filing, Proxy Statement, Sales Growth, Executive Compensation, Corporate Governance, Equity Incentive Plan, Board of Directors, Shareholder Meeting, Financial Performance, Medical Device Industry